Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of MDGL
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Madrigal Pharmaceuticals, Inc. stock price up 3.18% on Thursday
(Updated on Mar 28, 2024)

Buy or Hold candidate since Mar 15, 2024 Loss -1.23% PDF

The Madrigal Pharmaceuticals, Inc. stock price gained 3.18% on the last trading day (Thursday, 28th Mar 2024), rising from $258.81 to $267.04. During the last trading day the stock fluctuated 5.24% from a day low at $254.87 to a day high of $268.22. The price has fallen in 5 of the last 10 days but is still up by 9.64% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 37 thousand more shares were traded than the day before. In total, 436 thousand shares were bought and sold for approximately $116.34 million.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 16.98% during the next 3 months and, with a 90% probability hold a price between $227.80 and $337.76 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

MDGL Signals & Forecast

The Madrigal Pharmaceuticals, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $254.79 and $243.26. A breakdown below any of these levels will issue sell signals. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Monday, March 18, 2024, and so far it has fallen -5.72%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Madrigal Pharmaceuticals, Inc. stock

Madrigal Pharmaceuticals, Inc. finds support from accumulated volume at $265.68 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $13.35 between high and low, or 5.24%. For the last week, the stock has had daily average volatility of 4.90%.

Our recommended stop-loss: $252.91 (-5.29%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 8 days ago.)

Trading Expectations (MDGL) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect Madrigal Pharmaceuticals, Inc. to open at $263.38, and during the day (based on 14 day Average True Range), to move between $249.78 and $284.30, which gives a possible trading interval of +/-$17.26 (+/-6.46%) up or down from last closing price. If Madrigal Pharmaceuticals, Inc. takes out the full calculated possible swing range there will be an estimated 12.92% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $265.68 (0.51%) than the resistance at $270.37 (1.25%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Madrigal Pharmaceuticals, Inc. stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Madrigal Pharmaceuticals, Inc. stock to perform well in the short-term.

Current score: 3.870 Buy Candidate Unchanged

Predicted Opening Price for Madrigal Pharmaceuticals, Inc. of Monday, April 1, 2024

Fair opening price April 1, 2024 Current price
$263.38 ( 1.37%) $267.04

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for MDGL

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 276.73 3.63 %
R2 271.63 1.72 %
R1 268.48 0.538 %
Current price: 267.04
Support S1 258.28 -3.28 %
S2 255.13 -4.46 %
S3 250.03 -6.37 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 283.23 6.06 %
R2 272.98 2.22 %
R1 270.37 1.25 %
Current price 267.04
Support S1 265.68 -0.509%
S2 216.33 -18.99%
S3 201.44 -24.57%

FAQ

What is the symbol for Madrigal Pharmaceuticals, Inc. Stock and on which exchange is it traded?
The symbol for Madrigal Pharmaceuticals, Inc. is MDGL and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Madrigal Pharmaceuticals, Inc. Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Madrigal Pharmaceuticals, Inc. stock to perform well in the short-term.

How to buy Madrigal Pharmaceuticals, Inc. Stock?
Madrigal Pharmaceuticals, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Madrigal Pharmaceuticals, Inc. Stock.

What's the current price of Madrigal Pharmaceuticals, Inc. Stock?
As of the end of day on the 2024-03-28, the price of an Madrigal Pharmaceuticals, Inc. (MDGL) share was $267.04.

What is the 52-week high and low for Madrigal Pharmaceuticals, Inc. Stock?
The 52-week high for Madrigal Pharmaceuticals, Inc. Stock is $322.67 and the 52-week low is $119.76.

What is the market capitalization of Madrigal Pharmaceuticals, Inc. Stock?
As of the 2024-03-28, the market capitalization of Madrigal Pharmaceuticals, Inc. is 5.15B.

When is the next earnings date for Madrigal Pharmaceuticals, Inc.?
The upcoming earnings date for Madrigal Pharmaceuticals, Inc. is May 14, 2024.
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT